26 June 2021 | Saturday | News
Independent consultant Boston Healthcare Associates modelled the budget impact of using PromarkerD compared to the current standard of care, to proactively test for diabetic kidney disease in patients with type 2 diabetes but who otherwise have no sign of kidney disease.
It found the test—developed by Proteomics International—could result in net savings to Medicare and commercial insurers of USD384 billion over 10 years.
There are 31 million adults with diabetes in the US. Instigating the simple test, set at USD150 for an annual testing regime, would cost $8.9 billion annually, however, could produce savings of USD473 billion over ten years. Savings stem primarily from slowing the progression of diabetic kidney disease, followed by benefits from delaying or preventing dialysis and kidney transplants, and a reduction in dialysis crashes.
The findings will be presented at the virtual American Diabetes Association's 81st Scientific Sessions at 11:30am ET on Friday 25 June 2021 (presentation details below).
Proteomics International managing director Dr Richard Lipscombe said the research extends the initial modelling [ASX: 13 May] to emphasise the benefits of an early, accurate and cost-effective prognosis. "Testing patients with type 2 diabetes every 6-12 months with PromarkerD would enable early intervention for those at high-risk of developing diabetic kidney disease," he says.
"This would decrease the need for expensive late-stage interventions, such as dialysis and kidney transplants. It would also assist in stratifying which patients would receive new DKD preventative therapeutic treatments. The potential benefits to the patient and the healthcare system are enormous."
The PromarkerD test has received CE Mark registration and is currently available in Europe, with Proteomics International in advanced discussions to bring the test to the clinic in the US